A B S T R A C T The potential deleterious role of the proaggregatory vasoconstrictor, thromboxane A2, in endotoxic shock was investigated in rats. Plasma thromboxane A2 was determined by radioimmunoassay of its stable metabolite thromboxane B2. After intravenous administration of Salmonella enteritidis endotoxin (20 mg/kg), plasma thromboxane B2 levels increased from nondetectable levels (<375 pg/ml) in normal control rats to 2,054±524 pg/ml (n = 8), within 30 min to 2,071+429 at 60 min, and decreased to 1,119+319 pg/ml, at 120 min. Plasma levels of prostaglandin E also increased from 146±33 pg/ml in normal controls (n = 5) to 2,161+606 pg/ml 30 min after endotoxin (n = 5).
A B S T R A C T The potential deleterious role of the proaggregatory vasoconstrictor, thromboxane A2, in endotoxic shock was investigated in rats. Plasma thromboxane A2 was determined by radioimmunoassay of its stable metabolite thromboxane B2. After intravenous administration of Salmonella enteritidis endotoxin (20 mg/kg), plasma thromboxane B2 levels increased from nondetectable levels (<375 pg/ml) in normal control rats to 2,054±524 pg/ml (n = 8), within 30 min to 2,071+429 at 60 min, and decreased to 1,119+319 pg/ml, at 120 min. Plasma levels of prostaglandin E also increased from 146±33 pg/ml in normal controls (n = 5) to 2,161+606 pg/ml 30 min after endotoxin (n = 5).
In contrast to shocked controls, rats pretreated with imidazole, a thromboxane synthetase inhibitor, or essential fatty acid-deficient rats, which are deficient in arachidonate and its metabolites, did not exhibit significant elevations in plasma levels of thromboxane B2. Imidazole did not however inhibit endotoxininduced elevations in plasma prostaglandin E. Essential fatty acid deficiency significantly reduced mortality to lethal endotoxic shock. This refractoriness could be duplicated in normal rats pretreated with the fatty acid cyclo-oxygenase inhibitor, indomethacin (10 mg/kg), intravenously 30 min before endotoxin injection. Imidazole (30 mg/kg) administered intraperitoneally 1 h before or intravenously 30 min before endotoxin, also significantly (P < 0.01) reduced mortality from lethal endotoxin shock to 40% compared to a control mortality of 95% at 24 h. Likewise pretreatment with 13-azaprostanoic acid (30 mg/kg),
INTRODUCTION
During endotoxic shock there is an increased synthesis of prostaglandins from arachidonic acid (1) (2) (3) (4) . Their role in the pathogenesis of endotoxemia however, remains to be clearly elucidated (4-6). Endotoxic shock is also associated with thrombocytopenia, and pulmonary and mesenteric vasoconstriction (7) (8) (9) (10) . Thromboxane (TX)'A2, another arachidonic acid metabolite, is a potent vasoconstrictor and platelet aggregator (11) , thus raising the possibility that it may mediate these pathologic sequelae of endotoxemia. This postulate is further supported by previous studies demonstrating that essential fatty acid (EFA)-deficient rats that are depleted of prostaglandin and thromboxane precursors (12, 13) are resistant to endotoxic shock (14) .
Fatty acid cyclo-oxygenase inhibitors such as indomethacin block both the formation of prostaglandins and TXA2 from arachidonate. However, the discovery of selective thromboxane synthetase inhibitors such as imidazole (15, 16) , and the thromboxane antagonist, 13-azaprostanoic acid (17) , provide a means to specifically evaluate the role of TXA2 in endotoxic shock. Thus, this study was undertaken to determine: 1 Abbreviations used in this paper: EFA, essential fatty acid; PG, prostaglandin; TX, thromboxane.
(a) if TXA2 synthesis is increased during endotoxemia; and (b) the effects of indomethacin, imidazole, 13 -azaprostanoic acid and EFA deficiency on endotoxin-induced mortality in rats.
METHODS
Rats. All rats used in the experiments came from an inbred Long-Evans rat colony maintained by the investigators. The rats employed in these studies were 7-13 wk old.
Control rats were fed the usual colony diet that contained a minimum of 24% protein, 4.5% fiber, and 4% fat (Wayne Lab-Blox, Allied Mills, Inc., Chicago, Ill.). Of the fat content, 36.66% is linoleic acid, 2.45% linolenic acid, and 4.16% arachidonic acid.
EFA-deficient rats were fed a fat-free diet obtained from ICN Nutritional Biochemical (Cleveland, Ohio), consisting of 21.10% vitamin-free casein, 16.45% alphacel, 58.45% sucrose, 4.00% salt mixture, and vitamin supplements. The protocol for induction of EFA-deficiency has been described in Cook et al. (14) .
Radioimmunoassay of TXB2 and prostaglandin (PG)E. Blood, obtained via cardiac puncture, for TXB2 and PGE determinations was collected into plastic syringes that contained 0.1 ml indomethacin (100 gg/ml) dissolved in 0.1 M sodium phosphate buffer, pH 8.0, and three drops of heparin (1,000 U/ml). The blood was centrifuged (400 g) at 4°C in a refrigerated centrifuge and the plasma was collected and frozen at -20°C until extraction. To 1 ml of plasma, [3H]TXB2 or [3H]PGE2 (1,500 cpm) was added to correct for recovery losses. The plasma was acidified to pH 3.5 with formic acid and extracted twice with 3 vol of ethyl acetate. The ethyl acetate layer was removed and dried under N2. The dried extract was reconstituted and applied to a silicic acid column (0.5 g) and the PGE and TXB2 fraction was collected and dried under nitrogen (18) . The dried extract was reconstituted in 1 ml gelatin phosphate-buffered saline (18) . TXB2 was determined using a previously described radioimmunoassay. After incubation for 4 h at 37°C, free [3H]TXB2 was separated from bound using charcoal-dextran solution (18) . The antibody was provided by Dr. J. B. Smith, Cardeza Foundation, Philadelphia, Pa. The minimum detectable amount in 1 ml of plasma was -375 pg/ml. The antibody does not significantly cross-react ('0.04%) with other prostaglandins and the interassay V>ariability is 17% (n = 10) (18). PGE was determined using a previously described radioimmunoassay after conversion to PGB (19) .
Materials. The following were purchased from commercial sources: lipopolysaccharide, Boivin preparation of Salmonella enteritidis Difco. Laboratories, Detroit, Mich., control 690467; [5,6,8,9,11,12,14,15- Indomethacin and imidazole were dissolved in phosphatebuffered saline, and 13-azaprostanoic acid was prepared by dissolving 60 mg in 0.07 ml of ethanol, 0.25 ml of 1 N NaOH and 3.68 ml of saline.
Statistical analysis. Statistical analysis of differences in TXB2 levels was based upon the Student's t test (20) . The chi-square test (20) was employed for mortality studies. All data is expressed as mean+SE of the mean.
RESULTS
Plasma TXB2 time-course. The time-course of appearance of TXB2 in plasma after intravenous endotoxin (20 mg/kg) was determined at 30, 60, and 120 min (n = 8 per period) postinjection (Fig. 1) . Within 30 min after endotoxin injection, plasma TXB2 levels increased from nondetectable levels (<375 pg/ml) in normal control rats (n = 10) to 2,054±524 pg/ml (P < 0.01), peaked at 60 min, 2,071±429 pg/ml, and started to decline by 120 min to 1,119+319 pg/ml (Fig. 1) . Plasma PGE levels also increased from 146±33 pg/ml (n = 5) in nonshocked controls to 2,161+606 pg/ml (n = 5) 30 min after endotoxin administration. Plasma TXB2 levels failed to rise significantly at either 30 or 60 min after endotoxin in control rats pretreated 60 min before injection with imidazole (30 mg/kg i.p.) or in EFA-deficient (7-8 wk old) rats (Fig. 1) . Plasma PGE levels, however, remained elevated (1,669±475 pg/ml) in the imidazole pretreated group (n = 5) and did not vary significantly from shocked controls.
Mortality studies. Having established that imidazole and EFA-deficiency markedly reduced plasma TXB2 levels after endotoxin, we sought to determine if drugs that alter prostaglandin or TXA2 formation and EFA deficiency would improve survival from endotoxic shock. Within 5 h after endotoxin injection, mortality in shocked control rats was 50% (Table I) as compared to no mortality in EFA-deficient rats in FIGURE 1 Plasma TXB2 levels in control (CTRL), imidazole (IMID) treated, and EFA-deficient (EFAD) rats at 30, 60, 120 min after intravenous S. enteritidis endotoxin (20 mg/kg). Imidazole was administered intraperitoneally (30 mg/kg) 60 min before endotoxin. Data expressed as mean+SEM, n = 8-10 rats per group. Both imidazole-treated and EFA-deficient rats varied significantly from control (P < 0.01). (*) Minimum detectable plasma TXB2 was 375 pg/ml plasma. To further test the hypothesis that TXA2 is a significant pathogenic factor in endotoxic shock, we evaluated the effect of a TXA2 antagonist, 13-azaprostanoic acid. Rats received 13-azaprostanoic acid (30 mg/kg) intravenously, or its vehicle simultaneously with the injection of endotoxin. Within 4 h 50% of the shocked control rats (n = 14) were dead as opposed to only a 20% mortality in the 13-azaprostanoic acid-treated group. By 24 h no rats survived in the control group, whereas 50% of the rats (P < 0.01) pretreated with 13-azaprostanoic acid survived (Fig. 2) . Indeed 40% of these rats survived over an observed 72 h period.
DISCUSSION
The therapeutic efficacy of fatty acid cyclo-oxygenase inhibitors in improving endotoxic shock has not been reported to be uniformly beneficial (4) (5) (6) . Some of these variable results may reflect differences in the route and time of administration of the drugs as well as species variation. Our results however clearly demonstrate that intravenous administration of indo- (11) , increases early and markedly during endotoxic shock in rats. Imidazole significantly suppressed plasma TXB2 levels and reduced mortality from endotoxic shock, however, it did not significantly modify endotoxin induced elevations of PGE. These observations are consistent with the concept that imidazole exerts its protective action via inhibition ofthromboxane synthetase and/or shunting the metabolism of arachidonic acid to prostacyclin, an antiaggregatory, vasodilator prostaglandin (22, 23) . Imid- azole like indomethacin has numerous other effects (24) , therefore, the lower levels of plasma TXB2 may have been the result of a protective action of imidazole not mediated through inhibition of thromboxane synthetase. However, the postulate that TXA2 is a pathogenic factor in shock, is further supported by the observation that 13-azaprostanoic acid, a TXA2 antagonist (17) which does not alter arachidonic acid metabolism, nor effect the actions of prostacyclin, or PGE1, was effective in decreasing lethality caused by endotoxic shock. Furthermore, EFA-deficient rats that are refractory to the lethal endotoxic shock did not exhibit elevated plasma TXB2 levels. Because of the altered hemodynamic and thrombotic events observed during endotoxic shock (7) (8) (9) (10) , and the above observations, TXA2 may well be a primary factor eliciting the early cascade of pathogenic events ultimately progressing to irreversibility.
Our composite observations therefore suggest a potential benefit of three therapeutic modalities in endotoxic shock (i.e., fatty acid cyclo-oxygenase inhibitors and selective TXA2 synthetase inhibitors or antagonists). Because optimum doses and regimens of treatment are yet to be established, it is possible that selective inhibition of TXA2 formation, coupled with diversion of arachidonic acid metabolism toward increased prostacyclin synthesis (21, 22, 25) , or TXA2 antagonism, may prove to be more appropriate therapeutic approaches. The subsequent delineation of the tissue sources and potential pathogenic role of TXA2 in endotoxic shock clearly merits further investigation.
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